Experts have found that breast cancer drug Herceptin could keep new tumours away for more than four years.
They found that four years on, patients who received Herceptin -dubbed a 'wonderdrug' in 2005-are still 24 per cent less likely to have their tumours recur.
Women usually have surgery to remove the cancer and then receive chemotherapy. But after this, Herceptin can be used to stunt remaining cancer cells. It targets a protein, HER2, that fuels tumours.
When trial results for Herceptin were published at a US conference, the audience of oncologists stood up and applauded because it offered new hope for a group of women hard to treat.
Data revealed it cut risk of tumours recurring within a year by half. he latest date has shown that almost 79 per cent of women were alive with no new tumours four years after treatment, against 72 per cent given chemotherapy alone.
More on the wonderdrug.
No comments:
Post a Comment